Last reviewed · How we verify
PEX168
At a glance
| Generic name | PEX168 |
|---|---|
| Also known as | Polyethylene Glycol Loxenatide, Polythylene Glycol Loxenatide Injection |
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia (PHASE2, PHASE3)
- Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM Patients (NA)
- Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects (PHASE1)
- Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects (PHASE1)
- Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects (PHASE1)
- Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin (PHASE3)
- Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients (PHASE3)
- The Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEX168 CI brief — competitive landscape report
- PEX168 updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI